Skip Page Header

Home > An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds.

Advisory Council on the Misuse of Drugs. (2020) An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds. London: Advisory Council on the Misuse of Drugs.

[img]
Preview
PDF (An assessment of the harms of gamma-hydroxybutyric acid) - Published Version
1MB

This report reviews the evidence of harms of GHB and related compounds that have emerged since the UK ACMD’s last significant assessment of the risks of GHB and its prodrugs, GBL and 1,4-butanediol (1,4-BD) in [ACMD, 2008a]. The aim is to enable the ACMD to assess the level of harms associated with these compounds and to make recommendations to mitigate these harms – including (but not limited to) recommendations on the most appropriate classification and scheduling of these compounds under the MDA and MDR respectively.

Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Intervention Type
Policy
Date
November 2020
Pages
91 p.
Publisher
Advisory Council on the Misuse of Drugs
Corporate Creators
Advisory Council on the Misuse of Drugs
Place of Publication
London
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page